{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:39:31Z","timestamp":1788381571766,"version":"build-2803163510"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD), an emerging global health problem affecting 25\u201330% of the total population, refers to excessive lipid accumulation in the liver accompanied by insulin resistance (IR) without significant alcohol intake. The increasing prevalence of NAFLD will lead to an increasing number of cirrhosis patients, as well as hepatocellular carcinoma (HCC) requiring liver transplantation, while the current treatments for NAFLD and its advanced diseases are suboptimal. Accordingly, it is necessary to find signaling pathways and targets related to the pathogenesis of NAFLD for the development of novel drugs. A large number of studies and reviews have described the critical roles of bile acids (BAs) and their receptors in the pathogenesis of NAFLD. The gut microbiota (GM), whose composition varies between healthy and NAFLD patients, promotes the transformation of more than 50 secondary bile acids and is involved in the pathophysiology of NAFLD through the GM-BAs axis. Correspondingly, BAs inhibit the overgrowth of GM and maintain a healthy gut through their antibacterial effects. Here we review the biosynthesis, enterohepatic circulation, and major receptors of BAs, as well as the relationship of GM, BAs, and the pathogenesis of NAFLD in different disease progression. This article also reviews several therapeutic approaches for the management and prevention of NAFLD targeting the GM-BAs axis.<\/jats:p>","DOI":"10.3389\/fmicb.2022.908011","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T07:06:40Z","timestamp":1656313600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Yiming","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengna","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxi","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-jun","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41575-020-00406-0","article-title":"Nonalcoholic fatty liver disease: another leap forward.","volume":"18","author":"Abdelmalek","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives.","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1053\/j.gastro.2020.01.049","article-title":"Nonalcoholic Fatty Liver Disease: modulating Gut Microbiota to Improve Severity?","volume":"158","author":"Aron-Wisnewsky","year":"","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.","volume":"17","author":"Aron-Wisnewsky","year":"","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications.","volume":"60","author":"Bajaj","year":"2014","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/liv.13301","article-title":"Pathology of non-alcoholic fatty liver disease.","volume":"37","author":"Bedossa","year":"2017","journal-title":"Liver Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression.","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1745.e","DOI":"10.1053\/j.gastro.2016.02.073","article-title":"Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: causes or Effects?","volume":"150","author":"Betrapally","year":"2016","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/eurheartj\/ehr453","article-title":"Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?","volume":"33","author":"Bhatia","year":"2012","journal-title":"Eur. Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"22169096","DOI":"10.3390\/ijms22169096","article-title":"Bile Acid Signaling in Inflammatory Bowel Disease.","volume":"22","author":"Bromke","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.","volume":"10","author":"Caussy","year":"2019","journal-title":"Nat. Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1679.e","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"21155214","DOI":"10.3390\/ijms21155214","article-title":"Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"34055","DOI":"10.1038\/srep34055","article-title":"Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology.","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","article-title":"Characterization of fecal microbial communities in patients with liver cirrhosis.","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: regulation of synthesis.","volume":"50","author":"Chiang","year":"2009","journal-title":"J. Lipid Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3727\/105221618x15156018385515","article-title":"Bile Acid Metabolism in Liver Pathobiology.","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-nutr-082018-124344","article-title":"Bile Acids as Metabolic Regulators and Nutrient Sensors.","volume":"39","author":"Chiang","year":"2019","journal-title":"Annu Rev. Nutr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.","volume":"318","author":"Chiang","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2015.12.007","article-title":"Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules.","volume":"104","author":"Copple","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fmicb.2017.00563","article-title":"Gut Microbiota Modulation and Its Relationship with Obesity Using Prebiotic Fibers and Probiotics: a Review.","volume":"8","author":"Dahiya","year":"2017","journal-title":"Front. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","article-title":"Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.","volume":"21","author":"Dapito","year":"2012","journal-title":"Cancer Cell."},{"key":"B24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism.","volume":"17","author":"de Aguiar Vallim","year":"2013","journal-title":"Cell Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/hep.28572","article-title":"Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.","volume":"65","author":"Del Chierico","year":"2017","journal-title":"Hepatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.numecd.2017.10.014","article-title":"Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a prospective pilot study.","volume":"28","author":"Duarte","year":"2018","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s10620-020-06715-3","article-title":"Bile Acid Signaling in Inflammatory Bowel Diseases.","volume":"66","author":"Fiorucci","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies.","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8111358","DOI":"10.3390\/cells8111358","article-title":"Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.","volume":"8","author":"Gottlieb","year":"2019","journal-title":"Cells"},{"key":"B31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fphys.2016.00646","article-title":"TGR5, Not Only a Metabolic Regulator.","volume":"7","author":"Guo","year":"","journal-title":"Front. Physiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","article-title":"Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome.","volume":"45","author":"Guo","year":"","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40168-021-01101-1","article-title":"Review: microbial transformations of human bile acids.","volume":"9","author":"Guzior","year":"2021","journal-title":"Microbiome"},{"key":"B34","doi-asserted-by":"publisher","first-page":"12092598","DOI":"10.3390\/nu12092598","article-title":"TGR5 Signaling in Hepatic Metabolic Health.","volume":"12","author":"Holter","year":"2020","journal-title":"Nutrients"},{"key":"B35","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.biotechadv.2017.12.005","article-title":"Importance of microbial defence systems to bile salts and mechanisms of serum cholesterol reduction.","volume":"36","author":"Hor\u00e1c\u0306kov\u00e1","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"B36","doi-asserted-by":"publisher","first-page":"9050957","DOI":"10.3390\/microorganisms9050957","article-title":"Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.","volume":"9","author":"Hrncir","year":"2021","journal-title":"Microorganisms"},{"key":"B37","doi-asserted-by":"publisher","first-page":"104942","DOI":"10.1016\/j.phrs.2020.104942","article-title":"Bletilla striata oligosaccharides improve metabolic syndrome through modulation of gut microbiota and intestinal metabolites in high fat diet-fed mice.","volume":"159","author":"Hu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"11081712","DOI":"10.3390\/nu11081712","article-title":"Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).","volume":"11","author":"Ji","year":"2019","journal-title":"Nutrients"},{"key":"B39","doi-asserted-by":"publisher","first-page":"21093066","DOI":"10.3390\/ijms21093066","article-title":"The Molecular and Mechanistic Insights Based on Gut-Liver Axis: nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.","volume":"21","author":"Ji","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e1007954","DOI":"10.1371\/journal.ppat.1007954","article-title":"Promotion and induction of liver cancer by gut microbiome-mediated modulation of bile acids.","volume":"15","author":"Jia","year":"2019","journal-title":"PLoS Pathog."},{"key":"B41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.","volume":"15","author":"Jia","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"8096","DOI":"10.1038\/srep08096","article-title":"Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.","volume":"5","author":"Jiang","year":"2015","journal-title":"Sci. Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J. Hepatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","article-title":"Plasma metabolomic profile in nonalcoholic fatty liver disease.","volume":"60","author":"Kalhan","year":"2011","journal-title":"Metabolism"},{"key":"B45","doi-asserted-by":"publisher","first-page":"27.e","DOI":"10.1016\/j.chembiol.2018.10.003","article-title":"Bile Acid 7\u03b1-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of Secondary Bile Acids.","volume":"26","author":"Kang","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"8110501","DOI":"10.3390\/biomedicines8110501","article-title":"The Gut Microbiota: how Does It Influence the Development and Progression of Liver Diseases.","volume":"8","author":"Kanmani","year":"2020","journal-title":"Biomedicines"},{"key":"B47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1055\/s-0038-1669940","article-title":"Role of TGR5 (GPBAR1) in Liver Disease.","volume":"38","author":"Keitel","year":"2018","journal-title":"Semin. Liver Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis.","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab."},{"key":"B49","doi-asserted-by":"publisher","first-page":"201809302","DOI":"10.15252\/emmm.201809302","article-title":"The role of the microbiome in NAFLD and NASH.","volume":"11","author":"Kolodziejczyk","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1128\/jb.188.5.1979-1986.2006","article-title":"Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria.","volume":"188","author":"Kurdi","year":"2006","journal-title":"J. Bacteriol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.apsb.2014.12.009","article-title":"Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.","volume":"5","author":"Kwong","year":"2015","journal-title":"Acta Pharm. Sin. B."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD.","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD.","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug therapy.","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"7726","DOI":"10.1021\/acs.jafc.9b02523","article-title":"Polyphenol-Rich Loquat Fruit Extract Prevents Fructose-Induced Nonalcoholic Fatty Liver Disease by Modulating Glycometabolism, Lipometabolism, Oxidative Stress, Inflammation, Intestinal Barrier, and Gut Microbiota in Mice.","volume":"67","author":"Li","year":"2019","journal-title":"J. Agric. Food Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1021\/acs.jafc.9b00249","article-title":"Alterations of Bile Acids and Gut Microbiota in Obesity Induced by High Fat Diet in Rat Model.","volume":"67","author":"Lin","year":"2019","journal-title":"J. Agric. Food Chem."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/ijc.32563","article-title":"The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: an old story, yet mesmerizing.","volume":"146","author":"Liu","year":"2020","journal-title":"Int. J. Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.Cd-16-0932","article-title":"Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE(2)-Mediated Suppression of Antitumor Immunity.","volume":"7","author":"Loo","year":"2017","journal-title":"Cancer Discov."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1054.e","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis.","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1096\/fj.14-259515","article-title":"Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice.","volume":"29","author":"Mazagova","year":"2015","journal-title":"Faseb. J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/femsec\/fiu002","article-title":"Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease.","volume":"91","author":"Michail","year":"2015","journal-title":"FEMS Microbiol. Ecol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3945\/an.116.013151","article-title":"Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Adv. Nutr."},{"key":"B65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","article-title":"Role of Bile Acids in Metabolic Control.","volume":"29","author":"Molinaro","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"B66","doi-asserted-by":"publisher","first-page":"113102330","DOI":"10.3390\/cancers13102330","article-title":"The Role of the Microbiome in Liver Cancer.","volume":"13","author":"Moreno-Gonzalez","year":"2021","journal-title":"Cancers"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.","volume":"71","author":"Mouries","year":"2019","journal-title":"J. Hepatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep.26319","article-title":"Intestinal microbiota in patients with nonalcoholic fatty liver disease.","volume":"58","author":"Mouzaki","year":"2013","journal-title":"Hepatology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e0151829","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.","volume":"11","author":"Mouzaki","year":"2016","journal-title":"PLoS One"},{"key":"B70","doi-asserted-by":"publisher","first-page":"154457","DOI":"10.1016\/j.metabol.2020.154457","article-title":"Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.","volume":"116","author":"Nimer","year":"2021","journal-title":"Metabolism"},{"key":"B71","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/jam.13158","article-title":"Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob\/ob mice.","volume":"121","author":"Park","year":"2016","journal-title":"J. Appl. Microbiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"11055","DOI":"10.1074\/jbc.M117.784322","article-title":"Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.","volume":"292","author":"Pathak","year":"2017","journal-title":"J. Biol. Chem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection.","volume":"15","author":"Perez","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1152\/physrev.00049.2019","article-title":"Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging.","volume":"101","author":"Perino","year":"2021","journal-title":"Physiol. Rev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1152\/physiol.00028.2020","article-title":"Bile Acids, Their Receptors, and the Gut Microbiota.","volume":"36","author":"Poland","year":"2021","journal-title":"Physiology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis.","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","article-title":"Global chemical effects of the microbiome include new bile-acid conjugations.","volume":"579","author":"Quinn","year":"2020","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","first-page":".e861","DOI":"10.1016\/j.cgh.2013.02.015","article-title":"Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.","volume":"11","author":"Raman","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/intimm\/dxaa002","article-title":"Deficiency of TGR5 exacerbates immune-mediated cholestatic hepatic injury by stabilizing the \u03b2-catenin destruction complex.","volume":"32","author":"Rao","year":"2020","journal-title":"Int. Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4161\/gmic.25723","article-title":"Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship.","volume":"4","author":"Ridlon","year":"2013","journal-title":"Gut Microbes."},{"key":"B84","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.apsb.2015.01.006","article-title":"The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics.","volume":"5","author":"Ridlon","year":"2015","journal-title":"Acta Pharm. Sin B."},{"key":"B85","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","article-title":"Consequences of bile salt biotransformations by intestinal bacteria.","volume":"7","author":"Ridlon","year":"2016","journal-title":"Gut Microbes"},{"key":"B86","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/mog.0000000000000057","article-title":"Bile acids and the gut microbiome.","volume":"30","author":"Ridlon","year":"2014","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review.","volume":"313","author":"Rinella","year":"2015","journal-title":"Jama"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3389\/fmicb.2017.01581","article-title":"In Vitro Antibacterial Activity of Unconjugated and Conjugated Bile Salts on Staphylococcus aureus.","volume":"8","author":"Sannasiddappa","year":"2017","journal-title":"Front. Microbiol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"B91","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development.","volume":"11","author":"Schaap","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1053\/j.gastro.2014.01.020","article-title":"Interactions between the intestinal microbiome and liver diseases.","volume":"146","author":"Schnabl","year":"2014","journal-title":"Gastroenterology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11154-019-09512-0","article-title":"Dietary lipids, gut microbiota and lipid metabolism.","volume":"20","author":"Schoeler","year":"2019","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"B94","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jhep.2019.08.016","article-title":"Gut microbiome in HCC - Mechanisms, diagnosis and therapy.","volume":"72","author":"Schwabe","year":"2020","journal-title":"J. Hepatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.3748\/wjg.v27.i22.3010","article-title":"Role of bile acids in liver diseases mediated by the gut microbiome.","volume":"27","author":"Shao","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s1499-3872(17)60019-5","article-title":"Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.","volume":"16","author":"Shen","year":"2017","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"B97","doi-asserted-by":"publisher","first-page":"16602","DOI":"10.1111\/apt.16602","article-title":"Therapeutic aspects of bile acid signalling in the gut-liver axis.","volume":"2021","author":"Simbrunner","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"956.e","DOI":"10.1053\/j.gastro.2020.05.067","article-title":"Bile Acids Signal via TGR5 to Activate Intestinal Stem Cells and Epithelial Regeneration.","volume":"159","author":"Sorrentino","year":"2020","journal-title":"Gastroenterology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1098\/rspb.1947.0029","article-title":"Studies on the antibacterial properties of the bile acids and some compounds derived from cholanic acid.","volume":"134","author":"Stacey","year":"1947","journal-title":"Proc. R. Soc. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/s1499-3872(14)60307-6","article-title":"Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases.","volume":"14","author":"Stanimirov","year":"2015","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"B101","doi-asserted-by":"publisher","first-page":"114664","DOI":"10.1016\/j.taap.2019.114664","article-title":"Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis.","volume":"379","author":"Suga","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s13238-018-0546-3","article-title":"Insights into the role of gut microbiota in obesity: pathogenesis, mechanisms, and therapeutic perspectives.","volume":"9","author":"Sun","year":"2018","journal-title":"Protein Cell"},{"key":"B103","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.apsb.2019.02.004","article-title":"Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters.","volume":"9","author":"Sun","year":"2019","journal-title":"Acta Pharm. Sin. B."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1007\/bf01297092","article-title":"Antibacterial activity of bile salts against common biliary pathogens. Effects of hydrophobicity of the molecule and in the presence of phospholipids.","volume":"38","author":"Sung","year":"1993","journal-title":"Dig. Dis. Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.14309\/ctg.0000000000000131","article-title":"Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.","volume":"11","author":"Sydor","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1136\/gutjnl-2016-312729","article-title":"Gut microbiome and liver diseases.","volume":"65","author":"Tilg","year":"2016","journal-title":"Gut"},{"key":"B107","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.","volume":"24","author":"T\u00f8lb\u00f8l","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab."},{"key":"B109","doi-asserted-by":"publisher","first-page":"32002","DOI":"10.1038\/srep32002","article-title":"Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease.","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"B110","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/13543776.2018.1527906","article-title":"FXR modulators for enterohepatic and metabolic diseases.","volume":"28","author":"Wang","year":"2018","journal-title":"Exp. Opin. Ther. Pat."},{"key":"B111","doi-asserted-by":"publisher","first-page":"222.e","DOI":"10.1016\/j.celrep.2018.12.028","article-title":"Parabacteroides distasonis Alleviates Obesity and Metabolic Dysfunctions via Production of Succinate and Secondary Bile Acids.","volume":"26","author":"Wang","year":"2019","journal-title":"Cell Rep."},{"key":"B112","doi-asserted-by":"publisher","first-page":"G322","DOI":"10.1152\/ajpgi.00216.2019","article-title":"TGR5 signaling mitigates parenteral nutrition-associated liver disease.","volume":"318","author":"Willis","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/19490976.2019.1674124","article-title":"Diversification of host bile acids by members of the gut microbiota.","volume":"11","author":"Winston","year":"2020","journal-title":"Gut Microbes"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e62885","DOI":"10.1371\/journal.pone.0062885","article-title":"Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis\u2013a longitudinal study.","volume":"8","author":"Wong","year":"2013","journal-title":"PLoS One"},{"key":"B115","doi-asserted-by":"publisher","first-page":"111036","DOI":"10.1016\/j.biopha.2020.111036","article-title":"The gut microbiome-bile acid axis in hepatocarcinogenesis.","volume":"133","author":"Wu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B116","doi-asserted-by":"publisher","first-page":"103290","DOI":"10.1016\/j.ebiom.2021.103290","article-title":"Conjugated secondary 12\u03b1-hydroxylated bile acids promote liver fibrogenesis.","volume":"66","author":"Xie","year":"2021","journal-title":"EBioMed."},{"key":"B117","doi-asserted-by":"publisher","first-page":"9925","DOI":"10.18632\/oncotarget.24066","article-title":"Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice.","volume":"9","author":"Yamada","year":"2018","journal-title":"Oncotarget"},{"key":"B118","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drudis.2018.09.007","article-title":"Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases.","volume":"24","author":"Yang","year":"2019","journal-title":"Drug Discov. Today."},{"key":"B119","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.","volume":"64","author":"Younossi","year":"","journal-title":"Hepatology"},{"key":"B121","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"","journal-title":"Hepatology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrgastro.2017.72","article-title":"The gut microbiome and liver cancer: mechanisms and clinical translation.","volume":"14","author":"Yu","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.pharmthera.2018.04.005","article-title":"Bile acid regulation: a novel therapeutic strategy in non-alcoholic fatty liver disease.","volume":"190","author":"Yu","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B124","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.carbpol.2018.02.058","article-title":"Chitosan oligosaccharides improve the disturbance in glucose metabolism and reverse the dysbiosis of gut microbiota in diabetic mice.","volume":"190","author":"Zheng","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3748\/wjg.v25.i17.2019","article-title":"Microbial metabolites in non-alcoholic fatty liver disease.","volume":"25","author":"Zhou","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota.","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"B127","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.908011\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T07:06:43Z","timestamp":1656313603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.908011\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":127,"alternative-id":["10.3389\/fmicb.2022.908011"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.908011","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"article-number":"908011"}}